参考资料 1. Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer - PMC (nih.gov) 2. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer - Lung Cancer (lungcancerjournal.info) ...
[2]https://www.businesswire.com/news/home/20250409395229/en/U.S.-FDA-Grants-Full-Approval-of-VITRAKVI-larotrectinib-for-Adult-and-Pediatric-Patients-with-NTRK-Gene-Fusion-Positive-Solid-Tumors 编者按 如果您希望了解更多...
[1]Wang H, Li ZW, Ou Q, et al. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer Med. 2022;11(13):2541-2549. doi:10.1002/cam4.4561. [2]O'Haire S, Franchini F, Kan...
[2] Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.N Engl J Med. 2018;378(8):731-739.[3]Rolfo C. NTRK gene fusions: a rough diamond ready to sparkle.Lancet Oncol. 2020. [Epub ahead of print]u
Repotrectinib in a Patient With NTRK Fusion-Positive Pancreatic Carcinoma and Congenital Long QT SyndromeNeurotrophic tropomyosin receptor kinase (NTRK) gene fusions are potential targets for cancer therapy. Entrectinib and larotrectinib are first-generation TRK tyrosine kinase inhibitors (TKIs) ...
1.FDA approves larotrectinib for solid tumors with NTRK gene fusions.2.S. Lu, C. Chiu, Y. Yu.etc.111P - Entrectinib in Chinese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours.2022 ELCC.3. Xiao-Li Wei, Fenghua Wang, Xiao...
NTRK GENE FUSIONS SARCOMA SKIN CANCERSSKIN CANCERS THYROID CANCERS A 67-Year-Old Man With NTRK Fusion-Positive Metastatic Lung Cancer: Episode3 ByLuis E. Raez, MD Video Luis Raez, MD:Usually, when we find a genetic alteration that can be targeted, that is the preferred modality for treatme...
表格 1 拉罗替尼对不同实体瘤的疗效及缓解持续时间表源：Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children 基于优异的临床数据，拉罗替尼2018年11月在美国首次获批。2020年，该药更新了临床数据，在116例TRK融合癌患者中，均显示极高的缓解率和较长的缓解持续时间，且没有出副...
Mark A. Socinski, MD provides insight on biomarker testing to identify patients with NTRK gene fusion-positive non–small cell lung cancer. Read More FDA Clears Phase 1/2 Study of ABT-101 in Non–Small Cell Lung Cancer Jordyn Sava
5.Westphalen CB, Krebs MG, Le Tourneau C, et al. Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021;5(1):69. 6.Penault-Llorca F, Rudzinski ER, Sepulveda AR. Testing algorithm for identification of patients with TRK fusion ...